SCHEMBL374400

SCHEMBL374400

CCN1CCN(Cc2ccc(N)cc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.72
ALDH1A1 P00352 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.61
MAPT P10636 3/20 0.61
KDM4E B2RXH2 2/20 0.61
GAA P10253 2/20 0.61
RAD52 P43351 2/20 0.61
GFER P55789 2/20 0.61
TSHR P16473 1/20 0.56
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
TP53 P04637 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
POLB P06746 3/20 0.50
HRH3 Q9Y5N1 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
CA2 P00918 1/20 0.46
NCF1 P14598 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10690328 0.89 LMNA (0.80) LMNAALDH1A1KDM4EPOLBHRH3
SCHEMBL22802858 0.85 LMNA (0.73) LMNAALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL55983 0.84 LMNA (1.00) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL18049339 0.84 ALDH1A1 (0.69) LMNAALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL8254073 0.83 ALDH1A1 (0.74) LMNAALDH1A1SMN1; SMN2MAPTKDM4E
Hydrochloric Acid SCHEMBL1675964 0.82 LMNA (0.96) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL8529470 0.82 ALDH1A1 (1.00) LMNAALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL5625337 0.82 SIGMAR1 (0.75) LMNAALDH1A1KMT2APOLBSIGMAR1
SCHEMBL12717312 0.82 ALDH1A1 (0.71) LMNAALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL54966 0.81 ALDH1A1 (0.96) LMNAALDH1A1SMN1; SMN2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601287-B1 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS UNIV PALACKEHO (CZ) 2021-12-15 EP claimed
US-11028087-B2 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2021-06-08 US claimed
US-20200087306-A1 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-03-19 US claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2282995-B1 DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2015-08-26 EP claimed
US-8536175-B2 Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-09-17 US claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
CN-119431239-A Compounds, pharmaceutical compositions, kits and uses thereof 密执安大学评议会 2025-02-14 CN disclosed
CN-114751874-B 1-Benzyl-4-ethylpiperazine derivatives as TRPV4-KCa2.3 coupling promoters and uses thereof 江南大学 2025-01-24 CN disclosed
CN-113710241-B Substituted bicyclic and tetracyclic quinones and related methods of use 密执安大学评议会 2024-11-15 CN disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 US disclosed
WO-2005032548-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE CHIRON CORPORATION (US) 2005-04-14 WO disclosed
EP-1499311-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS Chiron Corporation (US) 2005-01-26 EP disclosed
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-06-24 US disclosed
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-05-06 US disclosed
WO-2003082272-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS CHIRON CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF LMNA 3011/4885ALDH1A1 1216/4885SMN1; SMN2 4020/4885
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF LMNA 2967/4885ALDH1A1 1008/4885SMN1; SMN2 4075/4885
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 LMNA 1416/4885ALDH1A1 3711/4885SMN1; SMN2 3500/4885
US-20200087306-A1 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS FLT3, CDK9, CDK6 LMNA 2956/4885ALDH1A1 811/4885SMN1; SMN2 4032/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 LMNA 1416/4885ALDH1A1 3711/4885SMN1; SMN2 3500/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 LMNA 196/4885ALDH1A1 4225/4885SMN1; SMN2 3123/4885
US-11028087-B2 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions FLT3, CDK9, CDK6 LMNA 2956/4885ALDH1A1 811/4885SMN1; SMN2 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.